Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone.
0/5 보강
APA
Lim JH, Ryu WK, Ryu JS (2026). Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone.. Lung cancer (Amsterdam, Netherlands), 213, 108938. https://doi.org/10.1016/j.lungcan.2026.108938
MLA
Lim JH, et al.. "Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone.." Lung cancer (Amsterdam, Netherlands), vol. 213, 2026, pp. 108938.
PMID
41605706 ↗
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus.
- DEL-1 is an Endogenous Senolytic Protein that Inhibits Senescence-Associated Bone Loss.
- Determinants of cervical cancer screening in Southeast Asia: A systematic review using the COM-B model and the theoretical domains framework.
- Smoking, Alcohol, and Abdominal Obesity Increase Gastric Cancer Risk after Helicobacter pylori Eradication.
- Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.